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Summary
 
Alveolar macrophages (AMs) avidly bind and ingest unopsonized environmental particles and
bacteria through scavenger-type receptors (SRs). AMs from mice with a genetic deletion of the
major macrophage SR (types AI and AII; SR
 
2
 
/
 
2
 
) showed no decrease in particle binding com-
pared with SR
 
1
 
/
 
1
 
 mice, suggesting that other SRs are involved. To identify these receptors,
we generated a monoclonal antibody (mAb), PAL-1, that inhibits hamster AM binding of un-
opsonized particles (TiO
 
2
 
, Fe
 
2
 
O
 
3
 
, and latex beads; 66 
 
6 
 
5, 77 
 
6 
 
2, and 85
 
 6 
 
2% inhibition, re-
spectively, measured by flow cytometry). This antibody identifies a protein of 
 
z
 
70 kD on the
AM surface (immunoprecipitation) that is expressed by AMs and other macrophages in situ. A
cDNA clone encoding the mAb PAL-1–reactive protein isolated by means of COS cell expres-
sion was found to be 84 and 77% homologous to mouse and human scavenger receptor
MARCO mRNA, respectively. Transfection of COS cells with MARCO cDNA conferred
mAb-inhibitable TiO
 
2
 
 binding. Hamster MARCO also mediates AM binding of unopsonized
bacteria (67 
 
6 
 
5 and 47 
 
6 
 
4% inhibition of 
 
Escherichia coli
 
 and 
 
Staphylococcus aureus
 
 binding by
mAb PAL-1). A polyclonal antibody to human MARCO identified the expected 
 
z
 
70-kD
band on Western blots of lysates of normal bronchoalveolar lavage (BAL) cells (
 
.
 
90% AMs)
and showed strong immunolabeling of human AMs in BAL cytocentrifuge preparations and
within lung tissue specimens. In normal mouse AMs, the anti-MARCO mAb ED31 also
showed immunoreactivity and inhibited binding of unopsonized particles (e.g., TiO
 
2
 
 
 
z
 
40%)
and bacteria. The novel function of binding unopsonized environmental dusts and pathogens
suggests an important role for MARCO in the lungs’ response to inhaled particles.
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N
 
ormal breathing inevitably results in deep penetration
into the lungs of various environmental particles and
microorganisms. The alveolar macrophage (AM)
 
1 
 
is the cell
that is primarily responsible for the binding, ingestion, and,
ultimately, clearance of inhaled particulate matter (1, 2). If
inhaled microorganisms are opsonized by antibodies and/or
complement, AMs can bind and phagocytose them via Fc
and C receptors (3, 4). AMs more frequently encounter var-
ious unopsonized environmental particles that they never-
theless bind and ingest with remarkable avidity (5, 6). The
AM response to inhaled particles ranges from abundant pro-
duction of inflammatory cytokines and reactive oxygen in-
termediates to simple ingestion and clearance with minimal
inflammation (7–9). The latter capacity is especially useful
for clearance of inert dusts and particles without risk of the
potentially damaging effects of an unnecessary inflammatory
response. Thus, receptor-mediated binding of inhaled parti-
cles and modulation of AM activation are important first
steps in the maintenance of lung homeostasis.
Previous work in our laboratory identified a role for
scavenger-type receptor(s) in this process (10). The scaven-
 
1
 
Abbreviations used in this paper:
 
 AM, alveolar macrophage; BAL, broncho-
alveolar lavage; BSS, balanced salt solution; CS, chondroitin sulfate; PI,
polyinosinic acid; RAS, right angle scatter; SR, scavenger receptor;
SRCR, scavenger receptor cysteine-rich domain.  
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ger receptors (SRs) are characterized by high-affinity bind-
ing of a relatively broad array of ligands such as modified
LDL, some (but not all) polynucleotides and polysaccha-
rides, and bacterial endotoxin (11, 12). There are three
classes of SRs, A, B, and C (13). The two class A SRs, type I
and type II, are homotrimeric glycoproteins composed of
three 77-kD monomers generated from alternative splicing
of a message encoded by a single gene (14, 15). SR-As are
abundant on monocytes and tissue macrophages as well
as other cells (13, 16, 17). A recently identified SR-A,
MARCO, also binds acetylated LDL (18, 19). MARCO,
like SR-A, binds bacteria but not yeast and is expressed on
peritoneal macrophages and splenic marginal zone mac-
rophages but has not been found in the lung (18–21).
The SR ligand polyinosinic acid (PI) caused a marked in-
hibition of AM binding of oxide particles, latex beads, fly ash,
and particles collected from ambient air (10, 22). PI also in-
hibited the uptake of quartz particles (SiO
 
2
 
) by AMs in vivo
(10). These data suggested that SR-like receptors mediate
nonopsonic phagocytosis of pollutant particles. Although
SR-A (I/II) seemed the most likely candidate, the use of PI
precluded precise identification of receptor(s), as this reagent
can inhibit more than one member of the SR family (11, 13).
In the studies reported here, we found that SR-A–defi-
cient AMs exhibited normal (comparable to wild-type)
ability to bind particles both in vitro and in vivo. To iden-
tify other scavenger-type receptors involved, we developed
an mAb capable of blocking hamster AM particle binding.
Using this mAb, we performed expression cloning for the
receptor, which is similar to mouse and human MARCO
in cDNA sequence homology and binding of bacteria. We
also show that mouse and human AMs express MARCO
and that mouse MARCO is involved in binding of un-
opsonized particles. The results indicate that MARCO is
likely to play an important role in the initial responses to
inhaled particles in the lung.
 
Materials and Methods
 
Reagents and Particles.
 
TiO
 
2
 
 and Fe
 
2
 
O
 
3
 
 were provided by Dr.
J. Brain (Harvard School of Public Health, Boston, MA). These
particles have been shown to be heterogeneous in size, with a
median diameter of 1.3 
 
m
 
m (23). Latex beads (1.0 
 
m
 
m in diame-
ter; sulfated polystyrene) that show green fluorescence after exci-
tation at 488 nm were obtained from Interfacial Dynamics Co.
All particles were suspended in balanced salt solution (BSS
 
2
 
 [124
mM NaCl, 5.8 mM KCl, 10 mM dextrose, and 20 mM Hepes])
as stock solutions and sonicated 
 
z
 
30 s before use. Anti-TNP
(PharMingen), anti-heparan sulfate mAbs (Seikagaku Corp.), anti–
human 
 
b
 
2 microglobulin mAb (PharMingen), and a nonspecific
rat IgG1 (PharMingen) were used as isotype-matched controls.
The anti–human MARCO antibody was raised in rabbits as de-
scribed (18). The anti–mouse MARCO mAb, ED31 (IgG1), was
provided by Dr. G. Kraal (Vrije Universiteit, Amsterdam, The
Netherlands) (21). All reagents not otherwise specified were ob-
tained from Sigma Chemical Co.
 
Cell Isolation and Flow Cytometric Assay of Particulate Binding.
 
SR-A–deficient mice were prepared as reported (24). Mice or
hamsters were killed by intraperitoneal pentobarbital injection.
 
AMs obtained by repeated lung lavage with BSS
 
2
 
 were centri-
fuged at 150 
 
g
 
 and resuspended in BSS
 
1
 
. AMs (2 
 
3
 
 10
 
5
 
 in 100 
 
m
 
l
BSS
 
1
 
) were preincubated with mAbs (100 
 
m
 
l hybridoma superna-
tant or 10 
 
m
 
g/ml mAb) or inhibitors (10 
 
m
 
g/ml) and 2.5 
 
m
 
g/ml cy-
tochalasin D for 5 min on ice in a 1-ml microfuge tube. After the
addition of probe sonicated particles or beads, the tubes were ro-
tated at 37
 
8
 
C for 30 min, placed on ice, and analyzed by flow cy-
tometry. Flow cytometry was performed using an Ortho 2150
cytofluorograph as previously described (25). AM uptake of parti-
cles was measured using the increase in the mean right angle scat-
ter (RAS) caused by these granular materials (25). Latex bead
binding is expressed as relative fluorescence.
 
Assay of Bacteria Binding.
 
Fluorescent-labeled, heat-killed bac-
teria (
 
Escherichia coli
 
 and 
 
Staphylococcus aureus
 
) and yeast (Zymosan)
were purchased from PharMingen. The bacteria binding assay
was performed exactly as described above, except that AMs were
incubated with either bacteria (5 
 
3
 
 10
 
7
 
) or yeast (2 
 
3
 
 10
 
5
 
) instead
of particles. Binding was measured by detecting AM-associated
fluorescence by flow cytometry.
 
In Vivo Particle Uptake.
 
Mice were anaesthetized with halo-
thane (4%), and 125 
 
m
 
l TiO
 
2
 
 (50 
 
m
 
g/ml) in BSS
 
1
 
 was instilled
into the lungs using a 22-gauge canula. Bronchoalveolar lavage
(BAL) was performed 30 min after instillation, and aliquots of
BAL were immediately analyzed by flow cytometry to quanti-
tate cell-associated particles.
 
Production of mAb.
 
BALB/c mice were immunized by intra-
peritoneal injection of 2 
 
3
 
 10
 
7
 
 hamster AMs. After 3 wk, mice re-
ceived another injection of 2 
 
3
 
 10
 
7
 
 AMs i.p., and 3 d later, spleens of
the mice were removed. The splenocytes were fused with a nonse-
creting mouse myeloma, P3U1, using polyethylene glycol 4000 and
cultured in DMEM containing hypoxanthine, aminopterin, and thy-
midine. After 2 wk, supernatants from hybridoma cultures were
screened for their ability to inhibit the adhesion of TiO
 
2
 
 to AMs.
 
Immunoprecipitation.
 
Hamster AM cell surface proteins were la-
beled with sulfo-NHS-LC-biotin (Pierce Chemical Co.) as per the
manufacturer’s suggested protocol and resuspended at a concentra-
tion of 4 
 
3
 
 10
 
7
 
 cells/ml in a 1% extraction buffer (1% Triton X-100,
50 mM Tris-HCl, 150 mM NaCl, 2 mM CaCl
 
2
 
, 2 mM MgCl
 
2
 
, and
5 mM iodoacetamide supplemented with 40 
 
m
 
g/ml PMSF, 2 
 
m
 
g/ml
aprotinin, and 10 
 
m
 
g/ml phenanthroline as protease inhibitors). The
lysates were precleared with rat anti–mouse IgM magnetic beads
(Dynabeads
 
®
 
; Dynal Inc.). Aliquots of lysate were incubated with
mAbs PAL-1 or RP-3 bound to rat anti–mouse IgM magnetic
beads overnight at 4
 
8
 
C. The immunoprecipitates were washed in
cold lysis buffer (without protease inhibitors), subjected to SDS-
PAGE, electroblotted to membrane filters, probed with avidin–
HRP conjugate (Pierce Chemical Co.), and developed using
chemiluminence reagent (Supersignal
 
Ò
 
; Pierce Chemical Co.).
 
Immunohistochemistry.
 
Cryostat sections of hamster tissues were
fixed in buffered 2% paraformaldehyde for 10 min, followed by
10 min in 100% cold (
 
2
 
20
 
8
 
C) methanol. After rinsing, immu-
nostaining was performed by sequential application of primary
antibody (mAb PAL-1 [5 
 
m
 
g/ml] or anti-heparan sulfate mAb
[5 
 
m
 
g/ml], goat anti–mouse IgG [1:50; Sternberger Monoclonals,
Inc.], and mouse peroxidase–antiperoxidase complex [1:100;
Sternberger Monoclonals, Inc.]), followed by labeling with chro-
mogen diaminobenzidine and H
 
2
 
O
 
2
 
. To increase sensitivity, an ad-
ditional cycle of secondary and peroxidase–antiperoxidase complex
was applied to sections, followed by a second chromogen reaction.
Paraffin sections of human lung tissue were immunostained using
an avidin–biotin complex protocol as previously described (26).
The slides were washed with water, counterstained with hematox-
ylin, dehydrated, and mounted for light microscopy. 
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Expression Cloning.
 
A hamster AM cDNA library prepared in
the pcDM8 vector (provided by Dr. B. Seed, Harvard Medical
School, Boston, MA; Paulauskis, J., unpublished data) was di-
vided into small pools and transfected into COS cells. The tran-
siently transfected COS cells were isolated by “panning” on mAb
PAL-1–coated plates, and plasmid DNA was reisolated and am-
plified as described (27). A receptor-positive pool was identified
by PAL-1 immunostaining of transfected COS cells after six
rounds of screening. This pool was subdivided repeatedly until
we obtained a single functional plasmid that upon transfection
conferred mAb PAL-1 reactivity to COS cells. Both strands of
the cDNA insert were sequenced at the Harvard University
Biopolymers Laboratory.
 
Western Blot Analysis.
 
Human AMs were collected by BAL
from healthy adults under an institutionally reviewed and ap-
proved protocol. AMs were washed and lysates prepared as de-
scribed above (see 
 
Immunoprecipitation
 
). The lysates were mixed
with 6
 
3
 
 reducing or nonreducing SDS–solubilization buffer,
subjected to SDS-PAGE, electroblotted to membrane filters,
probed with either control rabbit IgG or purified rabbit anti–human
MARCO antibody followed by avidin–HRP conjugate (Pierce
Chemical Co.), and developed using chemiluminence reagent
(Supersignal
 
Ò
 
; Pierce Chemical Co).
 
Statistics.
 
Data were analyzed using ANOVA and paired 
 
t
 
 test
components of a statistical software package (Statview; Abacus
Concepts). Significance was accepted when
 
 P 
 
, 
 
0.05.
 
Results
 
SR-A–deficient AMs Bind Unopsonized Particles.
 
To de-
termine whether SR-A (I/II) receptors mediate AM
binding of unopsonized particles, the binding of TiO
 
2
 
 by
SR-A (I/II)–deficient AMs (SR-A
 
2
 
/
 
2
 
) was tested and com-
pared with the binding of TiO
 
2
 
 by AMs from wild-type
mice (SR-A
 
1
 
/
 
1
 
). Microscopic evaluation of treated AMs
showed similar robust binding of TiO
 
2 
 
by both SR-A
 
2
 
/
 
2
 
and SR-A
 
1
 
/
 
1
 
 AMs (Fig. 1 A). Quantitation by flow cyto-
metric analysis of RAS increases showed that SR-A
 
2/2and
SR-A1/1 AMs demonstrated essentially identical particle
binding (Fig. 1 B). SR-A2/2 AMs also bound unopsonized
ferric oxide and fluorescent latex beads with comparable
avidity (data not shown). The SR ligand PI inhibited the
adhesion of TiO2 to both SR-A2/2 and SR1/1 AMs by 59 6
1% and 58 6 4%, respectively. The control polyanion,
chondroitin sulfate (CS), had no effect on particle adhesion.
To determine if the in vitro particle binding reflected in vivo
events, we measured particle binding to AMs after intratra-
cheal instillation of TiO2. SR-A–deficient or wild-type mice
were instilled with buffer alone or buffer containing TiO2.
After 30 min, mice were killed, BAL performed, and AM
uptake of TiO2 quantified by flow cytometry. As shown in
Fig. 1 C, both SR-A–deficient AMs and wild-type AMs
bound TiO2 in vivo to a comparable degree. Thus, SR-A
deficiency does not alter unopsonized particle binding by
AMs. These results suggested that SRs other than SR-A are
involved in unopsonized particle binding to AMs.
Effect of mAb PAL-1 on AM Binding of Particles. To de-
velop an mAb to the receptor that mediates particle bind-
ing, mice were immunized with hamster AMs, and hybrid-
omas were prepared and screened for mAbs that block AM
binding of TiO2. As shown in Fig. 2 and reported previ-
ously (10), the scavenger receptor ligand, PI, blocked AM
binding of TiO2 and served as a positive control for these
assays. A new mAb, PAL-1, inhibited AM binding of TiO2
by 67 6 5% (n 5 10). An isotype-matched control mAb
(anti-TNP) had no effect on AM binding of TiO2. We
next examined the effect of mAb PAL-1 on AM binding of
other environmental particles such as Fe2O3 or quartz
(SiO2) and the surrogate particle, latex beads. As shown in
Table I, PAL-1 inhibited AM binding of Fe2O3, SiO2, and
latex beads by 78 6 2, 52 6 24, and 85 6 4%, respectively.
Thus, mAb PAL-1 substantially inhibits AM binding of a
broad range of particles.
Immunoprecipitation of a Cell Surface Protein by mAb PAL-1.
To identify the protein(s) recognized by mAb PAL-1, im-
munoprecipitation experiments were carried out. AMs
were surface-labeled by sulfo-NHS-biotin (Pierce Chemical
Figure 1. SR-A–deficient and –sufficient AMs bind TiO2 equally. (A)
Representative photomicrograph showing approximately similar binding of
particles by SR-A–deficient (SR2/2) and wild-type (SR1/1) AMs incu-
bated with unopsonized TiO2 (original magnification 400). (B) SR2/2 and
SR1/1 AMs were pretreated with the SR blocker PI or the control polyan-
ion CS or left untreated, and their binding of TiO2 was determined by flow
cytometry. (C) SR2/2 and SR1/1 AMs show similar binding of TiO2 in
vivo as determined by intratracheal instillation of TiO2 followed by BAL
and flow cytometric analysis. TiO2 binding is expressed as increase in flow
cytometric RAS. The data represent the mean (6 SEM) of three separate
experiments (B) and three mice per treated group compared with one con-
trol (C). *Significantly different from TiO2 alone, P , 0.006.1500 Alveolar Macrophages Bind Environmental Particles through MARCO
Co.), and the cell surface molecules bound by PAL-1 were
analyzed by SDS-PAGE (Fig. 3). In both reducing and
nonreducing conditions, a single band with an apparent
molecular mass of 70 kD was detected in lysates of normal
AMs (Fig. 3). This band was absent from cells precipitated
with an isotype-matched (IgM) negative control antibody.
Tissue Localization of the PAL-1 Antigen. Immunostain-
ing of frozen sections from a range of normal hamster tis-
sues with PAL-1 showed that it reacted strongly with most
or all AMs, macrophages of lymph node sinuses, and von
Kupffer cells of the liver (Fig. 4 A). Macrophages in other
sites were also positive (e.g., splenic red pulp, intestinal
Peyer’s patch, thymus). Cross-reactions with other tissue
structures such as endothelial cells were not observed; nu-
merous other nonlymphoid tissues were negative (skin, brain,
heart, stomach, prostate, and kidney; data not shown).
Flow cytometric analysis showed that PAL-1 staining is de-
tected on AMs. Lymphocytes isolated from different lymph
nodes and thymocytes were negative (Fig. 4 B). Peritoneal
macrophages, neutrophils, and monocytes were predomi-
nantly negative (data not shown).
Expression Cloning of the Particle Adhesion Receptor. An
expression cloning protocol was used to identify the recep-
tor mediating AM binding of particles. When transfected
into COS cells, a cDNA clone conferred mAb PAL-1 reac-
tivity (Fig. 5, A and B). Both strands of the 1.6-kb insert
were sequenced. The sequence, including part of the 59-
and 39-untranslated regions, is shown in Fig. 6 A. From the
first ATG, we predict an open reading frame of 1452 bp,
which yields a protein of 483 amino acid residues with a
predicted molecular mass of 49.5 kD. GenBank searches of
the nucleotide and protein sequences revealed significant
homology to murine and human MARCO (84 and 77%
nucleotide identity with mouse and human MARCO cDNA,
respectively; 18, 19). We refer to this clone as hamster
MARCO. Amino acid identity between hamster, murine,
and human MARCO was 77 and 65%, respectively (Fig.
6 B). As shown in Table II, amino acid identity between
hamster, mouse, and human MARCO was highest in the
collagenous domain. The intracellular domain had 80%
identity between hamster and mouse MARCO, as com-
pared with 50% identity between hamster and human
MARCO. Hamster MARCO, like human MARCO, does
not have a cysteine residue in the spacer domain, but like
mouse MARCO, it retains two cysteines in the cytoplasmic
domain. The two potential carbohydrate attachment sites in
the spacer domain, the interruption of Gly-Xaa-Yaa repeats
in the collagenous domain, and all six cysteine residues in
the scavenger receptor cysteine-rich domain (SRCR) are
conserved between all three species (Fig. 6 B). Hamster
MARCO differs from both murine and human MARCO in
containing a shorter collagenous domain (237 amino acids).
MARCO Expression Confers mAb PAL-1–inhibitable TiO2
Binding to COS Cells. To confirm the role of MARCO
in particle binding, we transfected COS cells with hamster
MARCO cDNA. As shown in Fig. 5 C, COS cells trans-
fected with MARCO cDNA bound TiO2 (4.6-fold in-
crease in RAS). TiO2 binding by MARCO-transfected
Figure 2. The mAb PAL-1 blocks AM binding of TiO2. Hamster AMs
were untreated or pretreated with PI, CS, mAb PAL-1, and an isotype-
matched control mAb (IgM), and their binding of TiO2 was determined
by flow cytometry as described in Materials and Methods. TiO2 binding is
expressed as increase in flow cytometric RAS. The data represent mean
(6 SEM) of 10 separate experiments. *Significantly different from TiO2
alone, P , 0.001.
Table I. mAb PAL-1 Inhibits AM Binding of a Panel of 
Unopsonized Particles
Particle Percent inhibition
TiO2 (n 5 10) 67 6 5
Fe2O3 (n 5 2) 78 6 2
Sulfated latex beads (n 5 2) 85 6 3
SiO2 (n 5 3) 52 6 24
Hamster AMs were left untreated or pretreated with mAb PAL-1 or an
isotype-matched control mAb and their binding of particles determined as
described in Materials and Methods. Particle binding is expressed as percent
inhibition of TiO2 (n 5 10), Fe2O3 (n 5 2), latex bead (n 5 2), and SiO2
(n 5 3) binding by mAb PAL-1. No significant inhibition of particle bind-
ing was observed with a control IgM (range is from 218 to 7% inhibition).
Figure 3. Immunoprecipitation of
the AM surface protein recognized by
mAb PAL-1. Hamster AMs were sur-
face-labeled with sulfo-NHS-biotin,
extracted with Triton X-100, pre-
cleared with anti–mouse IgM mag-
netic beads, and immunoprecipitated
with mAb PAL-1 or a control IgM
bound to anti–mouse magnetic beads.
Immunoprecipitates were analyzed
using reducing (R) or nonreducing
(NR) SDS-PAGE as described in
Materials and Methods. Relative mo-
lecular mass is indicated (kD).1501 Palecanda et al.
Figure 4. Immunohistochemical detection of the molecule recognized by
PAL-1. (A) Photomicrographs of cytospins of hamster BAL cells. Frozen sections
of lung, liver, and lymph nodes were stained with mAb PAL-1 or an irrelevant
control mAb. Original magnification: 400 for BAL cells, 200 for tissue sections.
(B) The expression of the molecule recognized by mAb PAL-1 was analyzed by
flow cytometry. Single-cell suspensions prepared from the indicated organs
(CLN, cervical lymph node; MLN, mesenteric lymph node; PP, Peyer’s patch;
PMN, neutrophils) or hamster BAL (AM) were incubated with either mAb
PAL-1 or an isotype-matched control mAb followed by goat anti–mouse IgM–
FITC and analyzed by flow cytometry. The data are presented as relative fluo-
rescence intensity (mean channel number from flow cytometric analysis). White
bar, control; hatched bar, IgM; black bar, PAL-1.
COS cells but not untransfected COS cells was significantly
inhibited by the anti-MARCO mAb PAL-1 (47 6 6% in-
hibition; Fig. 5 C). Controls, including untransfected COS
cells and COS cells transfected with a plasmid encoding the
cDNA for hamster CD44, exhibited binding of TiO2 that
was inhibited by both PI and heparin (an agent that does
not inhibit AM binding of TiO2 [10]) but not mAb PAL-1
(data not shown). The constitutive heparin-sensitive parti-
cle-binding receptor on COS cells is different from
MARCO and remains to be identified (see Discussion).1502 Alveolar Macrophages Bind Environmental Particles through MARCO
Figure 5. (A and B) Transfection of COS cells with a cDNA clone (isolated by an ex-
pression cloning strategy) confers PAL-1 reactivity. COS cells were transfected with the
isolated cDNA clone (A) or the empty vector (B); cytospins prepared 48 h later, and they
were immunostained with mAb PAL-1. Control IgM antibody showed no labeling (not
shown). (C) Transfection of COS cells with MARCO cDNA (for sequence identification,
see Fig. 6) confers mAb PAL-1 inhibitable TiO2 binding. COS cells, transfected with
MARCO cDNA, were pretreated with mAb PAL-1 and a control mAb and their binding
of TiO2 determined using a flow cytometric assay. The data represent mean (6 SEM) RAS
increase of five separate experiments. *Significantly different from TiO2 alone, P , 0.01.
Figure 6. (A) Nucleotide and deduced protein sequences of hamster MARCO. Conserved cysteine residues in the SRCRs are boxed. Putative carbo-
hydrate attachment sites are circled. The consensus polyadenylation signal is underlined. The start ATG is indicated with an arrow. A kink in the collage-
nous domain is indicated by dotted underline. (B) Comparison of hamster, mouse, and human MARCO. Amino acids were aligned using the Align pro-
gram (GeneWorks package; Intelligenetics). Regions of identity are boxed. These sequence data are available from GenBank/EMBL/DDBJ under
accession number AF125191.1503 Palecanda et al.
Hamster MARCO Mediates AM Binding of Bacteria. To
further investigate the range of ligands for hamster MARCO,
we tested the effect of mAb PAL-1 on AM binding of un-
opsonized microorganisms. As shown in Fig. 7, mAb PAL-1
inhibited AM binding of E. coli and S. aureus by 67 6 5%
and 47 6 4%, respectively. PAL-1 had no effect on AM
binding of Zymosan. An isotype-matched control antibody
did not inhibit bacteria and yeast binding. Thus hamster
MARCO, like human and mouse MARCO (18, 19), me-
diates AM binding of bacteria but not yeast.
Expression of MARCO on Human Cells. The original
report of human MARCO did not detect MARCO ex-
pression in the lungs of a limited number of perinatal au-
topsy specimens (18). To evaluate whether adult human
AMs express MARCO, we performed immunologic analy-
sis using a polyclonal antibody to a peptide from domain V
of human MARCO (18). Histochemical analysis of hu-
man BAL cells (.90% AMs) and lung tissue showed that
the anti-MARCO antibody detects antigen on AMs but
not on other cells or surrounding tissue structures (Fig. 8,
A–D). We prepared lysates from human AMs (n 5 5) and
performed SDS/Western blot analysis. The anti–human
MARCO antibody reacted specifically with a discrete band
in all AM lysates, which ran at a relative molecular mass of
z70 kD (results from two samples are shown in Fig. 8 E).
No reactivity was seen with an irrelevant control antibody.
The same pattern was repeated when the analysis was per-
formed in nonreducing conditions (data not shown). Thus,
adult human AMs express MARCO.
SR-A–deficient AM Binding of TiO2 Is Inhibited by an Anti-
body to MARCO. An mAb to mouse MARCO has been
shown to block bacteria binding by mouse macrophages
(19). Although expression of MARCO was not detected in
mouse lungs in the original report, we found significant im-
munostaining (albeit weaker than that seen in human and
hamster AMs) of normal mouse AMs by the anti-MARCO
mAb ED31 (data not shown; see Discussion) (19). We there-
fore examined whether ED31 would block TiO2 binding by
mouse AMs. In these experiments, the SR inhibitor, PI, re-
duced TiO2 binding by 44 6 12 and 52 6 11% in SR2/2
and SR1/1 mice, respectively; the control polyanion CS had
no significant effect (n $ 3). Treatment of SR2/2 AMs with
ED31 blocked binding of TiO2 by 40 6 11% (n 5 4). TiO2
binding by SR1/1 was also inhibited by anti-MARCO mAb
treatment by 25 6 4% (n 5 3). Control IgG1 had no effect
on binding. Similar inhibition of mouse AM binding of un-
opsonized fluorescent latex beads and bacteria was seen (data
not shown). Thus, MARCO also functions to bind environ-
mental particles and bacteria in mouse AMs.
Discussion
In this study, we have identified MARCO as a major re-
ceptor on AMs for binding of unopsonized environmental
particles and certain microorganisms. The lung is constantly
exposed to environmental substances such as microbes,
pollutant particles, and allergens. The levels of ambient air
particles in the environment have been correlated with in-
creased morbidity and mortality (28–31). The clearance of
inhaled particulate matter is primarily mediated by AMs
through the process of phagocytosis (1, 2). AMs have been
previously shown to avidly phagocytose unopsonized parti-
cles (5, 6). However, the receptors on the AMs that recog-
nize and bind particles are not known. Here we have gen-
Table II. Amino Acid Identity between Hamster, Mouse, and 
Human MARCO
Hamster MARCO
domains
Percent amino acid identity
Human MARCO Mouse MARCO
Cytoplasmic 48 77
Transmembrane 61 78
Spacer 58 65
Collagenous 76 77
SRCR 65 77
Across all domains 65 77
Amino acid identity was determined by comparing the indicated puta-
tive domains with each other using the Align program in the Biology
Workbench (http://biology.ncsa.uiuc.edu).
Figure 7. Effect of mAb PAL-1 on bacteria and yeast binding by AMs.
Hamster AMs were left untreated or pretreated with PI, CS, mAb PAL-1, and
a control mAb (IgM). Following pretreatment, AM binding of E. coli, S. au-
reus, and the yeast particle Saccharomyces cerevisiae (Zymosan) was determined by
flow cytometry. The data represent mean (6 SEM) green fluorescence of four
separate experiments. *Significantly different from particle alone, P , 0.05.1504 Alveolar Macrophages Bind Environmental Particles through MARCO
erated an mAb, PAL-1, that blocked particle and bacteria
binding by AMs. Using mAb PAL-1 as a probe, we have
cloned the cDNA encoding for the receptor from an AM
cDNA library. Transfection of COS cells conferred mAb
PAL-1 reactivity and mAb PAL-1–inhibitable binding of
TiO2. By sequence homology and functional similarity, we
conclude that the receptor is the hamster homologue of
MARCO.
The recognition of phagocytic targets is mediated by
specific receptors on the phagocytes that either recognize
serum components (opsonins) bound to the particle or di-
rectly recognize molecular determinants on the target.
Thus, based on the mechanism of particle recognition,
phagocytosis is either opsonin-dependent or opsonin-inde-
pendent. The best characterized opsonin-dependent phago-
cytosis receptors are the Fcg receptor and the complement
receptor CR3 (3, 32). Recent advances have highlighted
the significance of other receptors, such as the collectin re-
ceptor, C1q, in opsonin-dependent phagocytosis (33, 34).
The opsonin-independent recognition of microorganisms
and apoptotic cells is mediated by receptors such as the
scavenger receptor, mannose receptor, vitronectin recep-
tor, asialoglycoprotein receptor, and the b2 integrins (35–
37). Based on the high expression of SRs on macrophages
and their broad specificity, we considered this class of
receptors as likely suspects for interaction with inhaled
particles. Indeed, we found that AM phagocytosis of un-
opsonized environmental dusts (TiO2, Fe2O3, SiO2) or fluo-
rescent latex beads is strongly inhibited by the SR blocker,
PI (10). To more precisely determine the role of SR-A in
this interaction, we examined the ability of AMs from SR-A
(I/II)–deficient mice (24) to bind particles. We showed
that both wild-type and SR-A–deficient macrophages
bound unopsonized TiO2 (Fig. 1), Fe2O3, and latex beads
essentially identically (data not shown). The scavenger
receptor ligand PI inhibited the binding of particles to
SR-A–deficient macrophages, suggesting that AMs express
additional SR-like molecules that mediate opsonin-inde-
pendent phagocytosis of particulate matter. To identify this
receptor, we generated a monoclonal antibody, PAL-1,
which blocked AM binding of particles (Fig. 2 and Table I).
Using this antibody, we have cloned the cDNA encoding
this receptor. Transfection of COS cells with this cDNA
clone confers mAb PAL-1 reactivity (Fig. 5 A). Impor-
tantly, transfection confers PAL-1–inhibitable binding of
TiO2 by COS cells (Fig. 5 C).
Interpretation of the COS cell transfection experiments
was complicated by the observation that COS cells constitu-
tively bind particles to a substantial degree. This indicated
the presence of endogenous particle adhesion receptor(s).
However, transfection of COS cells with MARCO but not
control plasmid or cDNA resulted in mAb PAL-1–inhib-
itable particle binding (Fig. 5 C). Importantly, the constitu-
tive COS cell receptor(s) for particles is sensitive to heparin
inhibition, whereas AM receptor–mediated particle bind-
ing is not heparin sensitive (10). Interestingly, transfection
with MARCO, in addition to conferring mAb PAL-1–inhib-
itable particle binding, substantially diminished the component
that was heparin inhibitable (data not shown). We specu-
late that the transfected cDNA competes with the endoge-
Figure 8. (A–D) Human AMs express MARCO. Immunostaining of normal volunteer BAL cytocentrifuge preparations (A) and surgical lung tissue
specimens (C) showed strong labeling by a rabbit anti–human MARCO antibody; control rabbit IgG showed only minimal nonspecific background
staining (B, D) (original magnification 400). (E) Lysates prepared from BAL cells collected from adult volunteers (2/5 similar results shown) were ana-
lyzed by reducing SDS-PAGE and immunoblotted with a rabbit anti–human MARCO antibody or control rabbit IgG (Ctrl). Relative molecular mass
standards are indicated (kD).1505 Palecanda et al.
nous COS cell particle receptor(s) for either surface expres-
sion or binding function. Existence of a particle-binding
receptor on nonphagocytes such as COS cells is not un-
precedented. The lung epithelial cell line A549 binds and
ingests unopsonized TiO2, and this binding can also be in-
hibited by PI and heparin (38).
The particle-binding receptor on hamster AMs is similar
to murine and human MARCO (Fig. 6). Murine MARCO
was originally identified by screening a murine macrophage
cDNA library with a human type XIII collagen probe.
Murine MARCO is a 210-kD trimer made up of three di-
sulfide-linked, 52-kD monomers and is expressed only on
macrophages in spleen and lymph nodes (19). Human
MARCO was recently cloned by screening human liver
and spleen cDNA libraries with a murine MARCO probe
(18). Human MARCO shares 68% sequence identity with
mouse MARCO. Hamster MARCO had higher sequence
identity to mouse than to human MARCO across all do-
mains (Table II). Interestingly, hamster MARCO has a
shorter collagenous domain (less 34 amino acids) than both
human and mouse MARCO. Also, like human MARCO,
hamster MARCO does not have a cysteine residue in the
spacer domain. The six cysteines in the cysteine-rich domain
are conserved in all three species (Fig. 6). The cysteine-rich
domain defines a recently identified family of proteins (39).
The true function of the SRCR is not clear. Hamster
MARCO, like mouse and human MARCO, binds bacteria
but not yeast (Fig. 7; references 19, 21).
The expression of MARCO on normal AMs merits dis-
cussion. Initially, both human and mouse MARCO were
not detected in normal lung (18, 19). Using Western blot
and immunolabeling techniques, we detected MARCO
expression in normal lavaged AMs and AMs presented in
diseased lungs (surgical specimens) (Fig. 8). The use of
adult AMs may explain the difference between this finding
and the absence of mRNA in neonatal lungs (18). In
mouse AMs, we have detected faint but reproducible im-
munoperoxidase labeling, using mAb ED31, of normal
BAL AMs. This antibody also partially blocks mouse AM
binding of particles, indicating that low levels of ED31
(MARCO) are present and functional on these cells. In these
studies, we used normal, healthy looking mice housed in
conventional facilities, not a “clean room” barrier facility.
Expression of MARCO is induced on lung and liver mac-
rophages in mice infected with Klebsiella pneumoniae (21). It
is possible that our mice expressed MARCO because of
low-level activation from their less clean environmental
surroundings, a possibility yet to be formally tested. It is
also noteworthy that both PI and anti-MARCO (ED31)
cause lower levels of inhibition of unopsonized particle
binding by mouse AMs compared with that seen with
hamster AMs. Whether this reflects a significant difference
(e.g., the presence of other receptor[s]), minor species, or
technical variables remains to be determined.
Our finding that MARCO mediates AM binding of par-
ticles defines a novel and immunologically important func-
tion for MARCO. As MARCO mediates binding of both
inert particles and potentially pathogenic microorganisms,
it will be interesting to determine how binding by MARCO
modulates AM bactericidal functions. Specifically, the laud-
able absence of AM activation that accompanies binding
(and ingestion) of inert environmental dusts may prove
harmful for encounters with viable pathogens. Additional
studies of the function of MARCO may provide more in-
sight into the role of AMs in the initial, innate response of
the lung to inhaled particles and pathogens.
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